Navigation Links
Mylan Launches Cabergoline Tablets
Date:12/5/2013

PITTSBURGH, Dec. 5, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its U.S.-based subsidiary Mylan Pharmaceuticals Inc. has launched Cabergoline Tablets USP, 0.5 mg. Cabergoline Tablets USP are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. Mylan received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product.

Cabergoline Tablets USP, 0.5 mg, had U.S. sales of approximately $41.67 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

Currently, Mylan has 178 ANDAs pending FDA approval representing $90.3 billion in annual sales, according to IMS Health. Forty of these pending ANDAs are potential first-to-file opportunities, representing $24.1 billion in annual brand sales, for the 12 months ending June 30, 2013, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,200 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately 40% of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 140 countries and territories. Our workforce of more than 20,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com


'/>"/>
SOURCE Mylan Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Mylan Completes Acquisition of Agila to Create Leading Global Injectables Platform
2. Elton John AIDS Foundation and Mylan Give $1 Million to Nigeria for the Elimination of Mother-to-Child Transmission of HIV
3. Mylan Announces Pricing of $2.0 Billion of Senior Notes
4. Mylan Applauds New Federal Legislation to Increase Anaphylaxis Preparedness in Schools
5. Mylan to Present at the 2013 Credit Suisse Healthcare Conference
6. Mylan Reports Third Quarter 2013 Adjusted Diluted EPS of $0.82
7. Mylan Supports Generic Drug Industrys Call on FDA to Uphold Consistent, Proven International Standard for Biosimilar Naming
8. Mylan to Speak at the Morgan Stanley Global Healthcare Unplugged Conference
9. Mylan to Speak at the Bank of America Merrill Lynch Global Healthcare Conference
10. Mylan Announces Completion of Transdermal Patch Facility Expansion Project in St. Albans, Vt.
11. Mylan Acquisition of Agila Receives Approval from Indias Foreign Investment Promotion Board and Cabinet Committee on Economic Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... Research and Markets has announced the addition of Jain ... and Companies" to their offering. ... , , Drug ... market value of drug delivery technologies and the anticancer drugs are ... to organs involved and the types of cancer as well as ...
(Date:12/2/2016)... -- Around the corners of world, cancer has infused ... present over earth. Cancer has become one of those ... time this is because of the increasing incidence rates ... steady increase in global cancer incidence with its associated ... of treatment, there is increasing interest in this stringent ...
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... ... On Dec. 2, 2016, CURE® magazine will host the 4th Annual MPN ... Heroes—eight individuals who have made a difference in the field of rare blood cancers ... demonstrating leadership within the MPN community and/or a commitment to individual patients. , This ...
(Date:12/2/2016)... , ... December 02, 2016 , ... ... the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s ... help provide scholarship funds for area students and operating support to UNCF-member institutions, ...
(Date:12/2/2016)... California (PRWEB) , ... December 02, 2016 , ... ... professionals, proudly announces the launch of its 60-day free trial program for all ... trip shipping make the offer a truly hassle free experience. , FlexiSpot’s unique ...
(Date:12/2/2016)... ... December 02, 2016 , ... The annual time frame to change Medicare ... Period), is ending December 7th. Currently-enrolled Medicare beneficiaries who are looking to switch from ... (Part D) need to make changes during this period order for their new policy ...
(Date:12/2/2016)... ... 02, 2016 , ... With the number of pain management programs available for ... find the one that works for them. When an inventor from Suisun City, Calif., ... and decided to share it with others. , He developed a prototype for PRO ...
Breaking Medicine News(10 mins):